Results 201 to 210 of about 98,145 (299)

Advancing high-throughput anti-HCV drug screening: a novel dual-reporter HCV replicon model with real-time monitoring. [PDF]

open access: yesRes Pharm Sci
Chitsombat K   +4 more
europepmc   +1 more source

Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies

open access: yesChemBioChem, Volume 27, Issue 9, 14 May 2026.
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci   +5 more
wiley   +1 more source

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 3, Page 871-882, May 2026.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura   +9 more
wiley   +1 more source

The usefulness of anti-HCV signal to cut-off ratio in predicting hepatitis C viremia and the effect of genotype differences on signal to cut-off ratio. [PDF]

open access: yesRev Assoc Med Bras (1992)
Sarıkaya B   +6 more
europepmc   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy